pharm edaily

[Seok Ji-hoen, Edaily Reporter] Hanmi Science, the holding company of Hanmi Pharmaceutical Group, and its key business unit, Hanmi Pharmaceutical, each held board meetings on March 5 to finalize nominees for their boards of directors. These candidates will be presented for approval at the regular shareholders’ meeting on March 26.

Exterior View of Hanmi Pharmaceutical Headquarters.

The group is implementing an advanced governance structure in which professional managers oversee operations, while major shareholders provide support and oversight. This initiative marks a new chapter for Hanmi Pharmaceutical Group as it strengthens its corporate governance.

Hanmi Science’s board has proposed four internal director nominees: Im Joo-hyun, vice chairman of Hanmi Science and Hanmi Pharmaceutical, Kim Jae-kyo, former vice president of Meritz Securities, Shim Byung-hwa, former executive director at Samsung Biologics and Kim Sung-hoon, former executive director at Hanmi Science. Additionally, three external director nominees have been selected, Choi Hyun-man, former CEO of Mirae Asset Securities, Kim Young-hoon, former judge at the Seoul High Court and Shin Yong-sam, professor at the Catholic University of Korea’s Seoul St. Mary’s Hospital.

Kim Jae-kyo, one of the nominees, has been appointed as the next CEO and recently joined Hanmi Science as vice chairman. Meanwhile, Shim Byung-hwa has been named the new chief financial officer (CFO) and has taken on the role of vice president.

Hanmi Pharmaceutical’s board, which also met on March 5, has put forward three nominees for its shareholders‘ meeting: Choi In-young, head of Hanmi Pharmaceutical’s R&D Center, as an internal director, Kim Jae-kyo, former vice president of Meritz Securities, as a non-executive director and Lee Young-gu, managing attorney at law firm Daeryuk Aju, as an external director.

A Hanmi Pharmaceutical Group spokesperson stated, “After overcoming various challenges over the past year, we are reinforcing our advanced governance structure and embarking on a new beginning. Through performance-driven innovation, we aim to grow alongside our customers and shareholders as a forward-looking enterprise.”